Outcomes among Patients with Mantle Cell Lymphoma Post-Covalent BTK Inhibitor Therapy in the United States: A Real-World Electronic Medical Records Study
Table 1
Patient characteristics.
Characteristic
Overall population (N = 946)
Patients who discontinued cBTKi therapy (N = 739)
Patients who received post-cBTKi therapy (N = 352)
Age, median years (range)
72.0 (33.1–88.5)a
72.7 (33.4–88.6)b
71.3 (36.2–88.6)c
Sex, n (%)
Male
710 (75.1)
560 (75.8)
268 (76.1)
Female
236 (24.9)
179 (24.2)
84 (23.9)
Race, n (%)
White
766 (81.0)
607 (82.1)
291 (82.7)
Black/African American
46 (4.9)
32 (4.3)
20 (5.7)
Asian
24 (2.5)
16 (2.2)
5 (1.4)
Other/unknown
110 (11.6)
84 (11.4)
36 (10.2)
Geographic region, n (%)
Midwest
256 (27.1)
204 (27.6)
92 (26.1)
Northeast
98 (10.4)
71 (9.6)
34 (9.7)
South
371 (39.2)
285 (38.6)
151 (42.9)
West
196 (20.7)
161 (21.8)
67 (19.0)
Missing/unknown
25 (2.6)
18 (2.4)
8 (2.3)
Practice setting, n (%)
Academic
298 (31.5)
239 (32.3)
117 (33.2)
Community
637 (67.3)
493 (66.7)
230 (65.3)
Missing/unknown
11 (1.2)
7 (0.9)
5 (1.4)
Year of MCL diagnosis, n (%)
2011
46 (4.9)
41 (5.5)
24 (6.8)
2012
71 (7.5)
58 (7.8)
28 (8.0)
2013
98 (10.4)
88 (11.9)
33 (9.4)
2014
99 (10.5)
84 (11.4)
45 (12.8)
2015
132 (14.0)
107 (14.5)
52 (14.8)
2016
115 (12.2)
89 (12.0)
48 (13.6)
2017
133 (14.1)
106 (14.3)
43 (12.2)
2018
137 (14.5)
103 (13.9)
49 (13.9)
2019
77 (8.1)
46 (6.2)
23 (6.5)
2020
38 (4.0)
17 (2.3)
7 (2.0)
Year of cBTKi discontinuation/last observed cBTKi (for those who did not discontinue)
2014
30 (3.2)
30 (4.1)
11 (3.1)
2015
63 (6.7)
62 (8.4)
31 (8.8)
2016
85 (9.0)
80 (10.8)
43 (12.2)
2017
111 (11.7)
98 (13.3)
45 (12.8)
2018
153 (16.2)
144 (19.5)
81 (23.0)
2019
167 (17.7)
155 (21.0)
70 (19.9)
2020
191 (20.2)
154 (20.8)
62 (17.6)
2021
146 (15.4)
16 (2.2)
9 (2.6)
Time from initial diagnosis, median months (range)
14.4 (0–116.4)d
24.0 (0.2–114.4)e
25.2 (1.2–114.8)f
Abbreviations: cBTKi = covalent bruton tyrosine kinase inhibitor; MCL = mantle cell lymphoma. aage at start of cBTKi therapy, bage at cBTKi discontinuation, cage at the start of post-cBTKi therapy, dtime from initial diagnosis of MCL to start of cBTKi therapy, etime from initial diagnosis of MCL to cBTKi discontinuation, ftime from initial diagnosis of MCL to start of post-cBTKi therapy.
